Glomerulocapillary miRNA response to HLA-class I antibody in vitro and in vivo

Falko M Heinemann,Peter T Jindra,Clemens L Bockmeyer,Philip Zeuschner,Juliane Wittig,Heike Höflich,Marc Eßer,Mahmoud Abbas,Georg Dieplinger,Katharina Stolle,Udo Vester,Peter F Hoyer,Stephan Immenschuh,Andreas Heinold,Peter A Horn,Wentian Li,Ute Eisenberger,Jan U Becker
DOI: https://doi.org/10.1038/s41598-017-14674-5
2017-11-06
Abstract:Changes in miRNA expression glomerular of capillaries during antibody-mediated rejection (ABMR) are poorly understood and could contribute to the deleterious inflammation and fibrosis of ABMR via suppression of target genes. A better understanding could lead to novel diagnostic tools and reveal novel therapeutic targets. We explored deregulated miRNAs in an glomeruloendothelial in vitro model of ABMR due to class I human leukocyte antigen (HLA) with and without complement activation. We studied a set of 16 promising candidate miRNAs in microdissected glomeruli a confirmation set of 20 human transplant biopsies (DSA+) compared to 10 matched controls without evidence for ABMR. Twelve out of these 16 glomerulocapillary miRNAs could successfully be confirmed as dysregulated in vivo with 10 upregulated (let-7c-5p, miR-28-3p, miR-30d-5p, miR-99b-5p, miR-125a-5p, miR-195-5p, miR-374b-3p, miR-484, miR-501-3p, miR-520e) and 2 downregulated (miR29b-3p, miR-885-5p) in DSA+ vs. Controls: A random forest analysis based on glomerular miRNAs identified 18/20 DSA+ and 8/10 controls correctly. This glomerulocapillary miRNA signature associated with HLA class I-DSA could improve our understanding of ABMR and be useful for diagnostic or therapeutic purposes.
What problem does this paper attempt to address?